Cargando…

Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways

Doxorubicin (DOX) is broadly used in treating various malignant tumors. However, its cardiotoxicity limits its clinical use. Roxadustat (FG-4592) is a new hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor and has been approved for treating anemia in chronic kidney diseases (CKD) patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Guangfeng, Chen, Hongbing, Wu, Mengying, Li, Yuanyuan, Gao, Ling, Huang, Songming, Zhang, Yue, Jia, Zhanjun, Xia, Weiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419679/ https://www.ncbi.nlm.nih.gov/pubmed/32848792 http://dx.doi.org/10.3389/fphar.2020.01191

Ejemplares similares

Radioprotective effects of roxadustat (FG‐4592) in haematopoietic system
por: Zhang, Pei, et al.
Publicado: (2018)

Roxadustat (FG-4592) Facilitates Recovery From Renal Damage by Ameliorating Mitochondrial Dysfunction Induced by Folic Acid
por: Li, Xue, et al.
Publicado: (2022)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

Roxadustat (FG-4592) abated lipopolysaccharides-induced depressive-like symptoms via PI3K signaling
por: Li, Axiang, et al.
Publicado: (2023)

Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation
por: Miao, A-Feng, et al.
Publicado: (2021)

Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action
por: Chang, Wei-Ting, et al.
Publicado: (2019)

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
por: Besarab, Anatole, et al.
Publicado: (2015)

Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3β/Nrf2 Pathway
por: Li, Xue, et al.
Publicado: (2020)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

Isoquercitrin Ameliorates Cisplatin-Induced Nephrotoxicity Via the Inhibition of Apoptosis, Inﬂammation, and Oxidative Stress
por: Wang, Hao, et al.
Publicado: (2020)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Mokko Lactone Alleviates Doxorubicin-Induced Cardiotoxicity in Rats via Antioxidant, Anti-Inflammatory, and Antiapoptotic Activities
por: Sirwi, Alaa, et al.
Publicado: (2022)

Osteoblast–Osteoclast Coculture Amplifies Inhibitory Effects of FG‐4592 on Human Osteoclastogenesis and Reduces Bone Resorption
por: Hulley, Philippa A, et al.
Publicado: (2020)

FG-4592 protects the intestine from irradiation-induced injury by targeting the TLR4 signaling pathway
por: Feng, Zhenlan, et al.
Publicado: (2022)

Preparation, characterization, antioxidant and antianemia activities of Poria cocos polysaccharide iron (III) complex
por: Zhang, Yue, et al.
Publicado: (2023)

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
por: Chen, Nan, et al.
Publicado: (2017)

Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity
por: Lin, Xiaoxiao, et al.
Publicado: (2023)

A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities
por: Hu, Li-Feng, et al.
Publicado: (2021)

The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model
por: Zhou, Muran, et al.
Publicado: (2019)

Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson’s Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function
por: Li, Xuan, et al.
Publicado: (2018)

Cardioprotective Roles of β-Hydroxybutyrate Against Doxorubicin Induced Cardiotoxicity
por: Liu, Yihai, et al.
Publicado: (2021)

MicroRNAs in doxorubicin-induced cardiotoxicity: The DNA damage response
por: Kawano, Ippei, et al.
Publicado: (2022)

FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models
por: Jiang, Yumin, et al.
Publicado: (2023)

Oleoylethanolamide as a New Therapeutic Strategy to Alleviate Doxorubicin-Induced Cardiotoxicity
por: Qin, Yeyu, et al.
Publicado: (2022)

Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS
por: Yu, Jing, et al.
Publicado: (2021)

Dimethyl Fumarate Ameliorates Doxorubicin-Induced Cardiotoxicity By Activating the Nrf2 Pathway
por: Hu, Xiaoliang, et al.
Publicado: (2022)

Shenmai Injection Protects Against Doxorubicin-Induced Cardiotoxicity via Maintaining Mitochondrial Homeostasis
por: Li, Lin, et al.
Publicado: (2020)

PKC-ζ Aggravates Doxorubicin-Induced Cardiotoxicity by Inhibiting Wnt/β-Catenin Signaling
por: Cao, Yan-Jun, et al.
Publicado: (2022)

The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin
por: Fu, Xiaoyu, et al.
Publicado: (2021)

The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells
por: Fujimaki, Ayaka, et al.
Publicado: (2023)

Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications
por: Fang, Tingting, et al.
Publicado: (2023)

DiOHF Protects Against Doxorubicin-Induced Cardiotoxicity Through ERK1 Signaling Pathway
por: Chang, Danqi, et al.
Publicado: (2019)

Heat Shock Protein 22 Attenuates Doxorubicin-Induced Cardiotoxicity via Regulating Inflammation and Apoptosis
por: Lan, Yin, et al.
Publicado: (2020)

Breviscapine remodels myocardial glucose and lipid metabolism by regulating serotonin to alleviate doxorubicin-induced cardiotoxicity
por: Li, Meng-Jiao, et al.
Publicado: (2022)

Protective effect of cafestol against doxorubicin-induced cardiotoxicity in rats by activating the Nrf2 pathway
por: Al-Kenany, Sara A., et al.
Publicado: (2023)

The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Wang, Lijun, et al.
Publicado: (2022)

Glabridin Prevents Doxorubicin-Induced Cardiotoxicity Through Gut Microbiota Modulation and Colonic Macrophage Polarization in Mice
por: Huang, Keqing, et al.
Publicado: (2019)

Resolvin D1 Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Inflammation, Oxidative and Endoplasmic Reticulum Stress
por: Wang, Menglong, et al.
Publicado: (2022)

SIRT1 activation and its effect on intercalated disc proteins as a way to reduce doxorubicin cardiotoxicity
por: Podyacheva, Ekaterina, et al.
Publicado: (2022)

Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy
por: Zhou, Ji-Chao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_reaafauni28gcdpdq25hmcpuc6